Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study.

Heart Rhythm Research Laboratory, Division of Cardiology, Oregon Health and Science University, Portland, Oregon.
Journal of the American College of Cardiology (Impact Factor: 15.34). 03/2006; 47(6):1161-6. DOI: 10.1016/j.jacc.2005.11.045
Source: PubMed

ABSTRACT We sought to evaluate the contribution of left ventricular (LV) dysfunction toward occurrence of sudden cardiac death (SCD) in the general population, and to identify distinguishing characteristics of SCD in the absence of LV dysfunction.
Patients who manifest warning symptoms and signs are more likely to undergo evaluation before SCD. Although prevalence of LV dysfunction in this subgroup may overestimate the prevalence in overall SCD, this is the only means of assessment in the general population.
All cases of SCD in Multnomah County, Oregon (population 660,486; 2002 to 2004) were prospectively ascertained in the ongoing Oregon Sudden Unexpected Death Study. We retrospectively assessed LV ejection fraction (LVEF) among subjects who underwent evaluation of LV function before SCD (normal: > or =55%; mildly to moderately reduced: 36% to 54%; and severely reduced: < or =35%). Of a total of 714 SCD cases (annual incidence 54 per 100,000), LV function was assessed in 121 (17%).
The LVEF was severely reduced in 36 patients (30%), mildly to moderately reduced in 27 (22%), and normal in 58 (48%). Patients with normal LVEF were distinguishable by younger age (66 +/- 15 years vs. 74 +/- 10 years; p = 0.001), higher proportion of females (47% vs. 27%; p = 0.025), higher prevalence of seizure disorder (14% vs. 0%; p = 0.002), and lower prevalence of established coronary artery disease (50% vs. 81%; p < 0.001).
In this community-wide study, only one-third of the evaluated SCD cases had severe LV dysfunction meeting current criteria for prophylactic cardioverter-defibrillator implantation. The SCD cases with normal LV function had several distinguishing clinical characteristics. These findings support the aggressive development of alternative screening methods to enhance identification of patients at risk.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Sudden cardiac death (SCD) accounts for ∼ 25% of all deaths in heart failure with preserved ejection fraction (HFpEF). However, strategies to identify HFpEF patients at a higher risk of SCD have not been developed.
    European Journal of Heart Failure 10/2014; · 5.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Das „Akute Koronarsyndrom ohne ST-Strecken-Hebung“ (NSTE-ACS) umfasst hinsichtlich des Schweregrads der Erkrankung und des damit verbundenen Risikos ein außerordentlich großes Spektrum. Daher ist bei Patienten mit vermutetem NSTE-ACS neben der Sicherung der Diagnose auch eine Risikostratifizierung erforderlich, um eine adäquate weitere klinische Versorgung einzuleiten. Im September 2011 sind überarbeitete Leitlinien der European Society of Cardiology (ESC) zur Diagnose und Therapie des NSTE-ACS erschienen. Wichtige Änderungen hinsichtlich der Diagnostik betreffen die Verwendung des hochsensitiven Troponins einschließlich der sich daraus ergebenden Möglichkeit eines „Fast-track“-Protokolls, den routinemäßig empfohlenen Einsatz der Echokardiographie und die Option zur Verwendung der CT-Koronarangiographie. Bezüglich der Risikostratifikation wird der Wert des GRACE Risk Score betont, zusätzlich ausdrücklich auf die Relevanz von Blutungskomplikationen hingewiesen und der Einsatz des CRUSADE-Risikoscores für Blutungen empfohlen. Hinsichtlich der Therapie werden u. a. neue Empfehlungen zum Gebrauch von Thrombozytenaggregationshemmern und hinsichtlich der Zeitvorgaben zur invasiven Diagnostik (24 h für Hochrisikopatienten) gegeben. Der Kommentar zur ESC-Leitlinie bzgl. Diagnostik und Therapie des akuten Koronarsyndroms ohne ST-Hebung fasst den Inhalt des Originaldokuments zusammen, weist auf relevante Neuerungen hin und berücksichtigt dabei spezielle Aspekte aus deutscher Sicht. Abstract Non-ST-elevation acute coronary syndromes (NSTE-ACS) comprise a wide spectrum of disease severities and mortality risks. Next to establishing the diagnosis, clinical management therefore also requires risk stratification in order to adequately select the intensity and urgency of further work-up and treatment. In September 2011 updated recommendations for the management of patients with NSTE-ACS were published by the European Society of Cardiology. Major innovations included the use of highly sensitive troponin assays, including the resulting possibility of establishing a fast-track protocol, the routine recommendation of echocardiography in all patients and the introduction of coronary computed tomography (CT) angiography as a possibility to rule out coronary disease in selected individuals. The importance of risk stratification is emphasized throughout the document and routine use of the GRACE risk score as well as the CRUSADE bleeding risk score is encouraged. The recommendations reflect the availability of new antithrombotic agents and new timelines for invasive work-up are introduced. This comment in German summarizes the ESC guidelines and highlights relevant amendments as compared to the previous version.
    Der Kardiologe 08/2012; 6(4):283-301.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Left ventricular (LV) diameter is routinely measured on the echocardiogram but has not been jointly evaluated with the ejection fraction (EF) for risk stratification of sudden cardiac death (SCD).
    Journal of the American Heart Association. 09/2014; 3(5).


Available from